What rules apply when I advertise GLP-1 weight loss drugs?
Advertising a GLP-1 weight loss program means passing four sets of rules at once. The FTC requires every health and weight loss claim to be truthful and backed by competent and reliable scientific evidence, including claims made through testimonials. The FDA treats any suggestion that a compounded GLP-1 is the same as, as safe as, or approved like Wegovy, Ozempic, or Zepbound as false or misleading, and it sent warning letters to 30 telehealth companies on March 3, 2026 and to 25 more on June 16, 2026 over exactly those claims. Google and Meta run prescription drug ads from telehealth companies only after certification, which in practice means LegitScript, an independent reviewer of online health businesses, and Meta limits those ads to adults 18 and older. State medical boards and consumer protection laws add their own rules. The brand that runs the ad owns every claim in it. On Tessic Health, the brand's LegitScript application is prepared and filed as part of setup, and every prescription behind the ad is a clinical decision by a licensed provider.
Reviewed September 11, 2026 · 8 min read
In short
- Every weight loss claim needs scientific proof, including claims made in testimonials.
- Never call a compounded GLP-1 FDA-approved, generic, or the same as a brand-name drug.
- Prescription drug ads on Google and Meta require LegitScript certification first.
- Meta weight loss and prescription drug ads can only target adults 18 and older.
- The brand owns its ad claims; the licensed provider owns the prescribing decision.
On this page
The rulebooks a GLP-1 ad has to pass
Each set of rules is enforced by a different body, and passing one does not clear the others.
| Rulebook | Who enforces it | What it asks of a GLP-1 ad |
|---|---|---|
| Truth in advertising | Federal Trade Commission (FTC) | Claims must be truthful, not misleading, and backed by competent and reliable scientific evidence before the ad runs. Testimonials and influencer posts count as the brand's own claims. |
| Drug claims | Food and Drug Administration (FDA) | Compounded drugs are not FDA-approved. Ads cannot say or imply that a compounded GLP-1 is approved, generic, or the same as Wegovy, Ozempic, Zepbound, or Mounjaro. |
| Ad platform policy | Google and Meta | Telehealth and prescription drug ads need certification: LegitScript on Meta, LegitScript or NABP plus Google's own healthcare certification on Google. Meta requires 18+ targeting in eligible countries. |
| State law | State medical boards and attorneys general | Rules on how licensed providers may appear in ads, consumer protection laws, and automatic renewal laws for subscriptions. |
The FDA's 2026 letters are summarized in Pharmaceutical Technology's coverage. Platform rules are in Meta's drugs and pharmaceuticals policy and Google's healthcare and medicines policy.
Start here
Do I need a medical license to start a telehealth company?
No. Licensed clinicians own the medical practice and the founder's company owns the business. Here is exactly who needs which license, and how the two companies fit together.
Read the guideWhy compounded GLP-1s get the closest look
During the national shortages of semaglutide and tirzepatide, pharmacies were allowed to compound copies of both drugs, and many telehealth brands built weight loss programs on them. The FDA has since declared both shortages over. Compounded versions can still be prescribed for individual patients in some circumstances, but they remain unapproved: the FDA has not reviewed any compounded product for safety, effectiveness, or quality.
That gap is what the 2026 warning letters targeted. The letters cited telehealth websites that described compounded semaglutide or tirzepatide as the same as the brand-name drugs or as FDA-approved. Brand names like Ozempic and Zepbound are also the manufacturers' trademarks, so using them to sell a compounded product can bring a trademark lawsuit on top of any FDA action.
Branded GLP-1s carry their own duties. When an ad names an approved drug, present its serious risks with the same prominence as its benefits. Semaglutide and tirzepatide both carry a boxed warning about thyroid C-cell tumors, and an ad that lists only the pounds lost gives a one-sided picture of the drug.
Claims that draw enforcement
These phrases and images show up again and again in warning letters, FTC cases, and rejected ads:
- "Same as Ozempic," "identical to Wegovy," or any wording that makes a compounded drug sound interchangeable with an approved one.
- "FDA-approved" or "generic semaglutide" for a compounded drug. No generic semaglutide or tirzepatide is sold in the United States, and compounded drugs are not approved.
- Brand-name trademarks such as Ozempic, Wegovy, Mounjaro, or Zepbound used to sell a product the manufacturer does not make.
- A promised number of pounds or a fixed timeline, such as "lose 30 pounds in 30 days."
- Guaranteed prescriptions, "no visit needed," or "approved in minutes," all of which tell the reader the medical evaluation is a formality.
- Before-and-after photos with results a typical patient will not see, or photos of people who were never patients.
- Fake countdown timers, invented "spots left" scarcity, and reviews the brand wrote or paid for without saying so.
What a compliant GLP-1 ad does
- Describes the service accurately: an online evaluation by a licensed provider, who prescribes only if treatment is appropriate.
- Says plainly when a product is compounded, and that compounded drugs are not FDA-approved.
- Cites results that match the evidence and gives their context, such as the average loss in a named clinical trial alongside diet and exercise.
- Shows the full price and what it includes, including whether medication is part of the monthly price.
- Speaks to the audience without asserting their condition. Meta's own examples accept "New diabetes treatment available" and reject "Do you have diabetes?", and the same logic applies to weight.
- Targets adults only. Meta requires 18+ targeting for weight loss ads and for prescription drug ads.
- Links to a landing page that makes the same claims, with the same disclosures, as the ad.
Before an ad goes live
Run every GLP-1 campaign through the same six checks, in this order.
Review every claim
List each claim in the ad, stated or implied, including what the images suggest. Rewrite anything the brand cannot prove today. What you can legally say in weight loss marketing has a line-by-line table.
Build the substantiation file
Substantiation means the proof behind a claim: the study, data, or program results that support it. File it, dated, before the ad runs. Evidence gathered after a complaint does not count.
Get certified
Prescription drug ads on Google and Meta need LegitScript certification, and Google adds its own healthcare certification on top. See how to get approved for Meta and Google ads.
Match the landing page
Platform reviewers and regulators read the page behind the ad. A careful ad that clicks through to "same as Ozempic" on the landing page fails both.
Check the current platform policy
Read the live Meta and Google health policies before each campaign. Meta updated its health and wellness standards on July 22, 2026, and both platforms revise these rules often.
Keep records
Save each version of the ad, its targeting, the claims review, and the evidence. If a regulator or platform asks, the brand can show what ran and why it was supported.
Who is responsible for what
| Task | Who owns it | On Tessic Health |
|---|---|---|
| Ad copy, images, and claims | The brand | The brand writes and approves its own marketing |
| Proof behind each claim | The brand | The brand keeps its own substantiation file |
| LegitScript application | The brand, under its own name | Prepared and filed by Tessic as part of setup; the brand reviews and signs |
| Whether a patient is prescribed a GLP-1 | The licensed provider | Every prescription is a clinical decision by a licensed provider |
| Pharmacy and medication cost | The pharmacy and the platform | Wholesale pass-through at 0% markup, with cold-chain shipping |
| Legal structure behind the brand | The founder's company and the medical practice | The MSO and friendly-PC structure, drafted for the client's ownership |
Why the provider, and never the brand, decides who gets treated is explained in Do I need a medical license to start a telehealth company?
Next steps for a GLP-1 brand
Read how to launch a GLP-1 weight loss clinic for the full launch sequence, how to get approved for Meta and Google ads for certification, and what you can legally say in weight loss marketing before writing the first ad. For keeping patients after the first order, see From visits to recurring care.
COMMON QUESTIONS
What founders ask next.
- Can I say "semaglutide" or "tirzepatide" in my ads?
- Naming the active ingredient is common, but the ad has to be accurate about what the patient receives. If the product is compounded, say so, and do not imply it is approved, generic, or identical to a brand-name drug. On Google and Meta, ads that promote prescription drugs also require certification, so plan for LegitScript before running them.
- Can I use Ozempic, Wegovy, Mounjaro, or Zepbound in my ads?
- Only to describe those exact products, when a provider may prescribe them and the patient receives them. The names are the manufacturers' trademarks. Using them to sell a compounded product misleads the reader and can bring both FDA attention and a trademark lawsuit from the manufacturer.
- Do I need LegitScript certification to advertise GLP-1s?
- For prescription drug ads on Google and Meta, yes. Meta requires online pharmacies and telehealth providers to be actively certified by LegitScript, and Google requires LegitScript or NABP certification plus its own healthcare certification. On Tessic Health, the brand's LegitScript application is prepared and filed as part of setup; LegitScript sets its own schedule and certification is never guaranteed.
- Can I show before-and-after photos in GLP-1 ads?
- Only of real patients who gave written permission, with unedited images and honest context about typical results. Meta's health and wellness policy requires weight loss ads to target people 18 and older and rejects sensational claims and promises of specific outcomes within a set timeframe. Read the current version, updated July 22, 2026, before using transformation images.
- What were the 2026 FDA warning letters about?
- On March 3, 2026 the FDA sent warning letters to 30 telehealth companies, and on June 16, 2026 it sent 25 more. The letters cited website claims about compounded semaglutide and tirzepatide, chiefly that the compounded drugs were the same as FDA-approved products or were approved themselves. The FDA has not reviewed compounded drugs for safety, effectiveness, or quality.
- Are the rules different for compounded and branded GLP-1s?
- The truth-in-advertising rules are the same. What changes is what an ad can accurately say. A branded drug is FDA-approved, so the ad can say that, and it should present the drug's serious risks alongside its benefits. A compounded drug is not approved, so the ad cannot say or imply it is, and it should state that the product is compounded.
- Who is liable if a GLP-1 ad breaks the rules?
- The advertiser, which is the brand. Platforms and pharmacies have duties of their own, but the FTC and FDA hold the company that published a claim responsible for it, including claims made by paid influencers and affiliates. Providers named or pictured in ads also answer to their state medical boards.
KEEP READING
The next questions on the list.
- Read the answer
Start here
Do I need a medical license to start a telehealth company?
- Read the answer
Advertising
What can I legally say in weight loss marketing?
- Read the answer
Advertising
How do I get my telehealth brand approved for Meta and Google ads?
- Read the answer
Launch by treatment
How do I launch a GLP-1 weight loss clinic?
- Read the answer
Compliance
What does HIPAA require of a telehealth brand owner?
- Read the answer
Launch planning
What do I need before my telehealth clinic sees its first patient?
SOURCES
- Pharmaceutical Technology: Why the FDA issued 30 warning letters to telehealth sites marketing compounded GLP-1s
- National Law Review: FDA's focus returns to compounding and telehealth, another wave of warning letters
- Venable: FDA's latest GLP-1 crackdown, what compounders and telehealth platforms need to know
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
- FTC: Health Products Compliance Guidance
- Meta: Drugs and pharmaceuticals advertising policy
Reviewed September 11, 2026. Tessic Health guides are general information for founders, not legal advice. Laws, agency guidance, and ad platform policies change; confirm the specifics for your business with health-care counsel. Tessic Health claims restate what tessichealth.com publishes on its pricing, platform, and security pages.